Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
accepted:
07
10
2021
pubmed:
12
10
2021
medline:
22
4
2022
entrez:
11
10
2021
Statut:
ppublish
Résumé
A new autoinflammatory syndrome related to somatic mutations of UBA1 was recently described and called VEXAS syndrome ('Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome'). To describe clinical characteristics, laboratory findings and outcomes of VEXAS syndrome. One hundred and sixteen patients with VEXAS syndrome were referred to a French multicentre registry between November 2020 and May 2021. The frequency and median of parameters and vital status, from diagnosis to the end of the follow-up, were recorded. The main clinical features of VEXAS syndrome were found to be skin lesions (83%), noninfectious fever (64%), weight loss (62%), lung involvement (50%), ocular symptoms (39%), relapsing chondritis (36%), venous thrombosis (35%), lymph nodes (34%) and arthralgia (27%). Haematological disease was present in 58 cases (50%): myelodysplastic syndrome (MDS; n = 58) and monoclonal gammopathy of unknown significance (n = 12; all patients with MGUS also have a MDS). UBA1 mutations included p.M41T (45%), p.M41V (30%), p.M41L (18%) and splice mutations (7%). After a median follow-up of 3 years, 18 patients died (15·5%; nine of infection and three due to MDS progression). Unsupervised analysis identified three clusters: cluster 1 (47%; mild-to-moderate disease); cluster 2 (16%; underlying MDS and higher mortality rates); and cluster 3 (37%; constitutional manifestations, higher C-reactive protein levels and less frequent chondritis). The 5-year probability of survival was 84·2% in cluster 1, 50·5% in cluster 2 and 89·6% in cluster 3. The UBA1 p.Met41Leu mutation was associated with a better prognosis. VEXAS syndrome has a large spectrum of organ manifestations and shows different clinical and prognostic profiles. It also raises a potential impact of the identified UBA1 mutation.
Sections du résumé
BACKGROUND
A new autoinflammatory syndrome related to somatic mutations of UBA1 was recently described and called VEXAS syndrome ('Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome').
OBJECTIVES
To describe clinical characteristics, laboratory findings and outcomes of VEXAS syndrome.
METHODS
One hundred and sixteen patients with VEXAS syndrome were referred to a French multicentre registry between November 2020 and May 2021. The frequency and median of parameters and vital status, from diagnosis to the end of the follow-up, were recorded.
RESULTS
The main clinical features of VEXAS syndrome were found to be skin lesions (83%), noninfectious fever (64%), weight loss (62%), lung involvement (50%), ocular symptoms (39%), relapsing chondritis (36%), venous thrombosis (35%), lymph nodes (34%) and arthralgia (27%). Haematological disease was present in 58 cases (50%): myelodysplastic syndrome (MDS; n = 58) and monoclonal gammopathy of unknown significance (n = 12; all patients with MGUS also have a MDS). UBA1 mutations included p.M41T (45%), p.M41V (30%), p.M41L (18%) and splice mutations (7%). After a median follow-up of 3 years, 18 patients died (15·5%; nine of infection and three due to MDS progression). Unsupervised analysis identified three clusters: cluster 1 (47%; mild-to-moderate disease); cluster 2 (16%; underlying MDS and higher mortality rates); and cluster 3 (37%; constitutional manifestations, higher C-reactive protein levels and less frequent chondritis). The 5-year probability of survival was 84·2% in cluster 1, 50·5% in cluster 2 and 89·6% in cluster 3. The UBA1 p.Met41Leu mutation was associated with a better prognosis.
CONCLUSIONS
VEXAS syndrome has a large spectrum of organ manifestations and shows different clinical and prognostic profiles. It also raises a potential impact of the identified UBA1 mutation.
Substances chimiques
Ubiquitin-Activating Enzymes
EC 6.2.1.45
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
564-574Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 British Association of Dermatologists.
Références
Beck DB, Ferrada MA, Sikora KA et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2020; 383:2628-38.
van der Made CI, Potjewijd J, Hoogstins A et al. Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of VEXAS patients. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2021.05.014.
Ferrada MA, Sikora KA, Luo Y et al. Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS syndrome. Arthritis Rheumatol 2021; 73:1886-95.
Tsuchida N, Kunishita Y, Uchiyama Y et al. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220090.
Bourbon E, Heiblig M, Gerfaud-Valentin M et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood 2021; 137:3682-4.
Arlet JB, Terrier B, Kosmider O. Mutant UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2021; 384:2163.
Barba T, Jamilloux Y, Durel CA et al. VEXAS syndrome in a woman. Rheumatology (Oxford) 2021; 60:e402-3.
Diarra A, Duployez N, Terriou L. Mutant UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2021; 384:2163-4.
Lacombe V, Kosmider O, Prévost M et al. Severe joint involvement in VEXAS syndrome: a case report. Ann Intern Med 2021; 174:1025-7.
Oganesyan A, Jachiet V, Chasset F et al. VEXAS syndrome: still expanding the clinical phenotype. Rheumatology (Oxford) 2021; 60:e321-3.
Sebastien Le JJ, Husson F. FactoMineR: an R package for multivariate analysis. J Stat Softw 2008; 56:11.
Huque MH, Moreno-Betancur M, Quartagno M et al. Multiple imputation methods for handling incomplete longitudinal and clustered data where the target analysis is a linear mixed effects model. Biom J 2020; 62:444-66.
Magnol M, Couvaras L, Degboé Y et al. VEXAS syndrome in a patient with previous spondyloarthritis with favorable response to intravenous immunoglobulin anti-IL17 therapy. Rheumatology (Oxford) 2021; 60:e314-15.
Grignano E, Jachiet V, Fenaux P et al. Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol 2018; 97:2015-23.
Wesner N, Drevon L, Guedon A et al. Gastrointestinal Behçet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review. Leuk Lymphoma 2019; 60:1782-8.
Huang H, Zhang W, Cai W et al. VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder. Exp Hematol Oncol 2021; 10:23.
Grayson PC, Patel BA, Young NS. VEXAS syndrome. Blood 2021; 137:3591-4.